SPRUCE BIOSCIENCES, INC. 8-K

What Happened

• Spruce Biosciences, Inc. filed an 8-K on April 21, 2026 disclosing an underwriting agreement dated April 20, 2026 for a public offering. The Company sold 1,150,000 shares of common stock at $50.00 per share and pre-funded warrants to purchase 50,000 shares at $49.99 each (exercise price $0.01).
• The underwriters (Leerink Partners LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc.) exercised their 30-day option in full on April 21, 2026 to buy an additional 180,000 shares at $50.00. The offering is expected to close on April 22, 2026, with gross proceeds of approximately $69.0 million before underwriting discounts, commissions and expenses.

Key Details

• Offering size: 1,150,000 common shares + 50,000 pre-funded warrants; additional 180,000 shares issued upon full exercise of the underwriters’ option.
• Prices: Common shares $50.00/share; pre-funded warrants sold at $49.99 (warrant exercise price $0.01).
• Ownership cap: Pre-funded warrants include a 4.99% beneficial ownership limitation (can be increased up to 9.99% with at least 61 days’ prior notice).
• Documents filed: Underwriting Agreement and form of Pre-Funded Warrant (Exhibits 1.1, 4.1), legal opinion of Cooley LLP (Exhibit 5.1), and press releases announcing launch and pricing (Exhibits 99.1 and 99.2).

Why It Matters

• This financing will bring in roughly $69.0M of gross proceeds, which affects the company’s cash position and potential funding for operations or development (the 8-K itself does not specify use of proceeds).
• The issuance increases shares outstanding and includes pre-funded warrants that can convert into shares subject to ownership limits, so investors should watch for dilution once warrants are exercised.
• The filing includes customary underwriting and indemnification terms and standard forward-looking statement disclosures.